Biotech entity
fda-approval is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention 5th U.S. Circuit Court of Appeals, the most common co-covered peer. Rosalie Markezich appears in 2 tracked Biotech stories from September 9, 2026.
Last mentioned: 2d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
fda-approval is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention 5th U.S. Circuit Court of Appeals, the most common co-covered peer. Rosalie Markezich appears in 2 tracked Biotech stories from September 9, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 5 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Rosalie Markezich. Shared-story counts are live from our verified record — not editorial picks.
5th Circuit hears mifepristone arguments
Louisiana AG Liz Murrill and Rosalie Markezich argue for tighter prescribing rules before a three-judge panel in New Orleans.
Louisiana pill access estimated at 770–900 monthly
A Society for Family Planning survey estimates that 770–900 Louisiana women per month obtained abortion pills from out-of-state providers under shield laws.
Supreme Court allows states to decide abortion issue
The Dobbs decision clears the path for state abortion bans and sets up the current legal battles over cross-border medication abortion.
For biopharma, the dispute over mifepristone prescribing rules is a test of FDA regulatory authority over an approved drug's risk evaluation and mitigation strategy. The case may influence how drug safety restrictions are litigated and how federal preemption applies to medication abortion.
Source: MedPage Today · chicagotribune.com
The biopharmaceutical sector is watching the 5th Circuit review of mifepristone's FDA prescribing rules. At least 60% of U.S. abortions use the two-drug regimen, making the drug's distribution and label conditions a high-stakes regulatory precedent.
Source: timesargus.com · bozemandailychronicle.com
Rosalie Markezich is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
